Skip to main content
. 2019 Dec 23;2019:5821589. doi: 10.1155/2019/5821589

Figure 1.

Figure 1

Prophylactic effect of MT-1303 on the development of proteinuria in MRL/lpr mice. MT-1303 was administered to MRL/lpr mice for 18 weeks from 8 weeks of age. (a) Proteinuria was assessed once a week using Ames urinalysis strips and was scored on a scale of 0–4 based on urinary protein concentrations as described in Materials and Methods. Each symbol represents the mean ± S.E.M. score of 12 animals. Statistical significance was calculated using the Shirley-Williams test by comparison with the vehicle-treated control group (∗p < 0.05, ∗∗p < 0.01). (b, c) Kidney sections from vehicle- (b) or MT-1303 0.3 mg/kg- (c) treated mice were labeled with anti-mouse CD3 mAb. (d, e) The axillary lymph nodes (d) and spleen (e) were weighed on the day after final administration. Results are expressed as the mean ± S.E.M. of 8 mice. (f–h) The number of T cells (d), B cells (e), and abnormal T cells (CD3+B220+) (f) was measured by flow cytometry. Results are expressed as the mean ± S.E.M. of 4 mice. (d–h) Statistical differences were calculated using the Williams test by comparison with the control (∗p < 0.05, ∗∗p < 0.01).